Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs ACCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACCL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

ACCL Overall Winner 6-Pillar Tally: TLPH 2 – 3 ACCL (1 Tie) Matrix Metrics: TLPH 4 – 6 ACCL

As of Nov 16, 2026, ACCL (ACCL) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas ACCL carries 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin).

  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile ACCL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs ACCL
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
ACCL US Equity Head-to-Head Winner
ACCL
Institutional Equity
$2.36
-0.84% 1D
Market Cap $33.5M
TTM Revenue $5.2M
Forward P/E N/M
Beta / 30D Vol -0.20β · 60% Vol
Unified Composite Score
63.4 / 100 BUY
Tech 68.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 39
RSI-14: 39.2 · SMA20: $2.54 · SMA50: $2.65

6-Pillar Scorecard Institutional Category Breakdown (TLPH 2 – 3 ACCL)

Columns: Metric · TLPH · ACCL
1. Valuation Multiples TLPH
Forward P/E 1.0x N/M
Trailing P/E 1.0x 120.0x
PEG Ratio N/M N/M
EV / Revenue N/M 6.5x
2. Growth & Scale TLPH
Revenue Growth (YoY) +0.0% +11.3%
Earnings Growth (YoY) +0.0% -62.5%
TTM Revenue (USD) $1,000 $5.2M
Market Cap $53.7M $33.5M
3. Profitability & Quality ACCL
Gross Margin N/A 42.4%
Operating Margin -1474700.0% 4.5%
Net Profit Margin 0.0% 5.5%
Return on Equity (ROE) -143.4% 7.0%
4. Balance Sheet & Cash Flow ACCL
Cash Generation (TTM) -$15M EBITDA $245,425 EBITDA
Cash Flow Margin N/A 4.7% EBITDA Mgn
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $0.43 Book/Sh · 7.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 118.4% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ACCL
OpEx & R&D Intensity N/A 37.9% of Rev ($2.0M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Consulting Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (4) vs ACCL (6)
Institutional Metric TLPH ACCL Criterion Row Edge
Market Capitalization
Scale
$53.7M $33.5M Larger Scale TLPH
Trailing P/E Ratio
Valuation
1.0x 120.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +11.3% Higher Growth ACCL
Operating Margin (TTM)
Profitability
-1474700.0% 4.5% Higher Margin ACCL
Net Profit Margin
Profitability
0.0% 5.5% Higher Margin ACCL
Return on Equity (ROE)
Capital Efficiency
-143.4% 7.0% Higher ROE ACCL
52-Week Range Position
Momentum
20% ($1–$2) 30% ($1–$5) Stronger Trend ACCL
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol -0.20β · 60% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 63.4 / 100 (BUY) Higher Composite ACCL
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $5.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) $245,425 EBITDA ($0.43 Book/Sh · 7.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACCL +6.52 pp
TLPH: -18.78% · ACCL: -12.26%
3M Horizon ACCL +13.11 pp
TLPH: -30.01% · ACCL: -16.9%
6M Horizon ACCL +64.63 pp
TLPH: -4.08% · ACCL: +60.55%
1Y Horizon TLPH +25.66 pp
TLPH: -18.01% · ACCL: -43.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs ACCL. Trailing 12-month operating profitability (TLPH -1474700.0% vs ACCL 4.5%) and valuation multiples (TLPH 1.0x vs ACCL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
ACCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.2M
Gross Margin42.4%
Op. Margin4.5%
ROE / Fwd P/E7.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACCL Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $33.5M market capitalization and 4.5% operating margin.
OpEx & R&D Reinvestment 37.9% of Rev ($2.0M)
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs ACCL Key Questions & Quantitative Answers

As of Nov 16, 2026, ACCL (ACCL) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas ACCL carries 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin). Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile ACCL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLPH leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with ACCL at +11.3% YoY revenue growth and -62.5% YoY earnings growth on $5.2M TTM revenue (42.4% gross margin, 4.5% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $5.2M for ACCL. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus 37.9% of Rev ($2.0M) (0 disclosures) for ACCL.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas ACCL trades at N/M Forward P/E, 120.0x Trailing P/E, N/M PEG, and 6.5x EV/Revenue (4.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus ACCL (7.0% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, ACCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.